EUVIMEDEUVIMED entdecken
Crossref

KRT80 in hepatocellular carcinoma plays oncogenic role via epithelial–mesenchymal transition and PI3K / AKT pathway

Ruheng Hua, Xiyue Yan, Jun He, Nuwa Wu, Wangjianfei Yu, Pengfei Yu, Lei Qin iD

IUBMB Life · 2025

DOI: 10.1002/iub.2925 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IUBMB Life, 2025. Verfasst von Ruheng Hua und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Epithelial-Mesenchymal Transition, Proto-Oncogene Proteins c-akt. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: National Natural Science Foundation of China for Young Scientists, Postgraduate Research & Practice Innovation Program of Jiangsu Province, Project of Nantong Health College of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hepatocellular carcinoma (HCC), a globally prevalent form of cancer, is featured by aggressive growth and early metastasis. Elucidating the underlying mechanism and identifying the effective therapy are critical for advanced HCC patients. In the study, we detect that KRT80 was upregulated in HCC samples. HCC patients with higher KRT80 are associated with worse overall survival after surgery. Gain‐of and loss‐of function studies show that KRT80 enhanced HCC cells proliferation, migration, invasion, and angiogenesis, whereas its silencing abolishes the effects in vivo and in vitro. Mechanistic investigation shows that KRT80 may function as an independent prognostic risk factor and act as an oncogene by influencing EMT and modulating the PI3K/AKT signaling pathway. Together, these findings suggest that KRT80 may be a potential oncogene and a good indicator in predicting prognosis. Targeting KRT80 can offer new insights into the prevention and treatment of HCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsEpithelial-Mesenchymal TransitionProto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesCell ProliferationGene Expression Regulation, NeoplasticCell MovementSignal TransductionHumansMaleAnimalsFemaleMicePrognosisMiddle AgedBiomarkers, TumorMice, NudeCell Line, TumorXenograft Model Antitumor AssaysMice, Inbred BALB CApoptosis

Stichwörter der Autor:innen

EMTHCCKRT80PI3Kangiogenesis

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of General Surgery, The First Affiliated Hospital of Soochow University, Suzhou, China.
  • Department of Gastrointestinal Surgery, Affiliated Hospital of Nantong University, Nantong, China.
  • Department of Nursing, Nantong Health College of Jiangsu Province, Nantong, China.
  • Department of General Surgery, Affiliated Huishan Hospital of Xinglin College, Nantong University, Wuxi Huishan District People's Hospital, Wuxi, China.

ORCID-Profile: Lei Qin

Förderung

  • National Natural Science Foundation of China for Young Scientists
  • Postgraduate Research & Practice Innovation Program of Jiangsu Province
  • Project of Nantong Health College of Jiangsu Province

Zitieren

APA

Hua, R., Yan, X., He, J., Wu, N., Yu, W., Yu, P., & Qin, L. (2025). KRT80 in hepatocellular carcinoma plays oncogenic role via epithelial–mesenchymal transition and PI3K / AKT pathway. IUBMB Life. https://doi.org/10.1002/iub.2925

Vancouver

Hua R, Yan X, He J, Wu N, Yu W, Yu P, et al. KRT80 in hepatocellular carcinoma plays oncogenic role via epithelial–mesenchymal transition and PI3K / AKT pathway. IUBMB Life. 2025. doi:10.1002/iub.2925

BibTeX
@article{Hua2025,
  author = {Hua, Ruheng and Yan, Xiyue and He, Jun and Wu, Nuwa and Yu, Wangjianfei and Yu, Pengfei and Qin, Lei},
  title = {KRT80 in hepatocellular carcinoma plays oncogenic role via epithelial–mesenchymal transition and PI3K / AKT pathway},
  journal = {IUBMB Life},
  year = {2025},
  doi = {10.1002/iub.2925}
}
Kostenlos starten →